Carisma Therapeutics Inc. Asset Resilience Ratio
Carisma Therapeutics Inc. asset resilience ratio. Carisma Therapeutics Inc. (CARM) has an Asset Resilience Ratio of 3.04% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Carisma Therapeutics Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Carisma Therapeutics Inc. (2022–2024)
Asset resilience ratio of Carisma Therapeutics Inc. from 2022 to 2024. This chart shows how Carisma Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read how much debt does Carisma Therapeutics Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Carisma Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Carisma Therapeutics Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $925.00K | 3.04% |
| Total Liquid Assets | $925.00K | 3.04% |
Asset Resilience Insights
- Limited Liquidity: Carisma Therapeutics Inc. maintains only 3.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Carisma Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Carisma Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Carisma Therapeutics Inc. Asset Resilience Ratio by Year (2022–2024)
Carisma Therapeutics Inc. asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Carisma Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.04% | $925.00K | $30.46 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $89.55 Million | -- |
| 2022-12-31 | 38.53% | $27.80 Million | $72.15 Million | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more